Interface Biologics Announces New V.P., Business Development
04 déc. 2018 08h00 HE
|
Interface Biologics Inc
TORONTO, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical...
Interface Biologics Completes Pre-IND Meeting with U.S. FDA on Epidel® Technology for treatment of Posterior Inflammatory Eye Diseases
27 nov. 2018 08h00 HE
|
Interface Biologics Inc
TORONTO, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical...
Interface Biologics Announces the Extension of its Licensing Agreement with Fresenius Medical Care
09 févr. 2016 07h30 HE
|
Interface Biologics Inc.;Fresenius Medical Care
TORONTO, CANADA--(Marketwired - Feb. 9, 2016) - Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to...
Interface Biologics Announces Series B Financing Round With DSM and BDC Capital
13 janv. 2015 07h30 HE
|
Interface Biologics Inc.
TORONTO, ONTARIO--(Marketwired - Jan. 13, 2015) - Interface Biologics Inc. (IBI), an innovative developer of biomedical-polymer technologies which improve the safety and effectiveness of...
Interface Biologics and Q3 Medical Devices Sign Agreement to Develop Next Generation Drug Coated Balloon with Kinesyx(TM) Technology
14 janv. 2014 07h30 HE
|
Interface Biologics Inc.
TORONTO, ONTARIO--(Marketwired - Jan. 14, 2014) - Interface Biologics Inc. (IBI), and Q3 Medical Devices Limited are pleased to announce the signing of a joint development and commercialization...
Interface Biologics' CSO Paul Santerre receives NSERC Synergy Innovation Award from Governor General
05 mars 2013 07h30 HE
|
Interface Biologics Inc.
TORONTO, ONTARIO--(Marketwire - March 5, 2013) -
Editors Note: There is a photo associated with this press release.
Interface Biologics Inc. (IBI), a privately held...
Interface Biologics Appoints Sandra Beach Lin to Board of Directors
02 oct. 2012 07h30 HE
|
Interface Biologics Inc.
TORONTO, ONTARIO--(Marketwire - Oct. 2, 2012) - Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to...
Interface Biologics Announces Licensing Partner AngioDynamics has Received FDA Clearance for BioFlo(TM) PICC with Endexo(TM) Technology
06 sept. 2012 07h30 HE
|
Interface Biologics Inc.
TORONTO, ONTARIO--(Marketwire - Sept. 6, 2012) - Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to...
Interface Biologics Announces Licensing Agreement With Navilyst Medical
25 oct. 2011 08h30 HE
|
Interface Biologics Inc.
TORONTO, CANADA--(Marketwire - Oct. 25, 2011) - Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to...
Fresenius Medical Care Executes Exclusive Interface Biologics License Agreement
12 juil. 2011 08h30 HE
|
Interface Biologics Inc.
TORONTO, ONTARIO--(Marketwire - July 12, 2011) - Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to...